Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma

Eur J Pediatr. 2015 Nov;174(11):1503-9. doi: 10.1007/s00431-015-2561-1. Epub 2015 May 16.

Abstract

Infantile hemangiomas are the most common benign childhood tumor that may have functional and/or cosmetic complications. We aimed to compare the clinical efficacy of propranolol alone and propranolol primed with systemic corticosteroids on the outcome of infantile hemangioma. A prospective randomized study included 40 infants aged less than 9 months with cutaneous hemangiomas. Patients were randomly assigned into two groups: group A were given oral prednisolone for the initial 2 weeks combined with oral propranolol, while group B were given oral propranolol alone for 6 months. The median age of the studied patients was 4.5 months (ranged 4 weeks-8 months). Sequential determination of the dimensions of the hemangiomas based on direct measurement and photographic analysis were performed. A significant reduction in the size of the lesions was found in group A in the 2-, 4-, and 8-week evaluation compared to group B (p < 0.001) with no statistical difference in the ultimate 6 month response (p = 0.134). Multiple logistic regression showed that early treatment before 6 months of age (OR 9.82, p = 0.007) and combined treatment with propranolol and prednisolone (OR 10.71, p = 0.006) were the predictors of best response.

Conclusion: Combining propranolol with corticosteroids gives a faster response and should be considered in treating life- or function-threatening hemangiomas.

Keywords: Combined treatment; Infantile hemangioma; Propranolol.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Adrenergic beta-Antagonists / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Glucocorticoids / therapeutic use*
  • Hemangioma / drug therapy*
  • Hemangioma / pathology
  • Humans
  • Infant
  • Male
  • Prednisolone / therapeutic use*
  • Propranolol / therapeutic use*
  • Prospective Studies
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Treatment Outcome

Substances

  • Adrenergic beta-Antagonists
  • Glucocorticoids
  • Prednisolone
  • Propranolol